ArticleHeliyon2025
Adverse outcome pathway-based assessment of pulmonary toxicity from the
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LncPrep + 96kb inhibits ovarian fibrosis by upregulating prolyl oligopeptidase expression.Molecular medicine reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the increasing use of biocides globally and their widespread application in various formulations, the understanding of the toxicity of biocide mixtures remains limited. We previously identified cetylpyridinium chloride and dinotefuran as a potential binary biocidal combination associated with pulmonary fibrosis, based on two intersecting adverse outcome pathways (AOPs) using the molecular initiating events (MIE) modeling method and in vitro testing. These compounds activate or inhibit toll-like receptor 4 (TLR4) and peroxisome proliferator-activated receptor-gamma (PPAR-γ), which are associated with pathways having the potential to cause pulmonary fibrosis. In this study, we aimed to validate these AOPs by assessing the toxicity of cetylpyridinium chloride and dinotefuran mixture. Sixty C57BL/6 male mice were exposed to either dinotefuran or cetylpyridinium chloride or a mixture of the two via intratracheal instillation (ITI) to examine the synergistic effects of MIE and key events (KEs) within putative AOPs. Various parameters, including clinical and histopathological indicators, changes in body weight and organ weight, inflammatory cell distribution, and inflammatory cytokine expression in the bronchoalveolar lavage fluid (BALF), were analyzed. Additionally, key indicators such as TLR4, NF-κB, TNF-α were investigated to validate the mechanistic aspects of putative AOPs associated with pulmonary fibrosis. We observed significant changes in body weight and neutrophil count, recognized indicators of inflammation, along with inflammatory cell infiltrates, in the group exposed to the mixture of the two biocides. Moreover, increased levels of markers associated with epithelial-mesenchymal transition (EMT) and fibrosis (TNF-α, Acta2, IL-1β, and MMP9), as well as elevated levels of TGF-β, a common downstream signaling factor of TLR4 and PPAR-γ, were identified. Collectively, our findings highlight the potential toxic effects of a mixture of these two biocides in an in vivo model and confirmed the effective function of the putative AOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.